Lung Cancer

LUNGMAP

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

---

EA5162 **SUSPENDED**

Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR

---

NRG LU002 (NCT03137771) (Temporarily Suspended 11/12/21)

Maintenance systemic therapy versus consolidative sterotactic body radiation therapy (SBRT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer: A randomized phases II/III trial.

---

ECOG E4512 (NCT02201992) **SUSPENDED** – Must have Consented to ALCHEMIST A151216 Trial

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

---

A151216 (NCT02194738) ALCHEMIST

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

---